Amwell Q3 2026 Earnings Call - AMERICAN WELL CORP

Explicit Guidance:

• Q4 FY2026: Revenue expected between $48M and $50M; Adjusted EBITDA expected from break-even to a positive $1M.
• Full Year FY2026 (Raised): Revenue guidance increased to $204M–$206M (prior: $195M–$205M); Adjusted EBITDA expected as a loss of $6.9M–$7.9M (prior: loss of $12M–$16M); Full-year AMG visit volume expected at the high end of the range (1.32M–1.37M visits).
• FY2027 Guidance: No specific numerical guidance provided for full-year 2027; management confirmed they will provide FY2027 full-year guidance on February 16, 2027.
• Cash Flow & EBITDA: Management targets positive cash flow from operations and positive Adjusted EBITDA for the fourth quarter of 2026.

Business-Segment Outlook:

• Subscription Revenue: Sequential decline of 6.8% in Q3; Q4 outlook shows stability with a expectation that major churn events from 2024–2025 are behind the company, though minor natural churn may persist.
• AMG (Amwell Medical Group): Revenue per visit increased 11% YoY to $79; Virtual primary care visits growing ~41% YoY; Full-year visit volume guidance maintained at the high end of the previously communicated range.
• Behavioral Health (SilverCloud): Significant investment to scale SilverCloud into the US market; anticipated to be a key growth driver with clinical outcomes (60–78% improvement in moderate/severe depression) serving as proof points.
• Platform Model: Strategic shift toward outcome-based pricing models where revenue share scales with utilization and savings generated, moving away from pure SaaS recurring revenue as clinical services grow.
• Customer Activation: Goal to address single-digit engagement rates; activation initiatives (on-demand engagement) demonstrated 3x usage rates when fully enabled.

Market and Competitive Outlook:

• Customer Demand Shift: Health plans and employers are shifting purchases from "access" to "engagement and outcomes" due to 8–11% projected cost increases in 2027 and stagnant premiums.
• Pricing Trends: Expectation of pricing mechanisms morphing from fixed SaaS fees to variable, performance-based fees tied to clinical and financial traction.
• Competitive Landscape: Industry-wide "vendor sprawl" and member confusion are creating opportunities for Amwell's unified platform; AI is lowering barriers for new entrants, increasing the need for a trusted platform to validate outcomes.
• Growth Drivers: Significant upside anticipated in "same-store growth" (activating remaining addressable population of 90M lives) and pipeline expansion from non-client payers/government agencies.

Macro / Industry Outlook:

• Healthcare Costs: Projected to rise 8–11% in 2027; technology-enabled care viewed as a primary lever for cost containment.
• AI Adoption: 30% of adults now use AI for health info monthly (up from 16% two years ago); AI is accelerating program creation but increasing integration complexity for buyers.
• Regulatory/Government: Federal procurement rules govern the VA contract; DHA contract is in final negotiation phases.
• Economic Conditions: Payer budget constraints limit infrastructure investments, favoring consolidated platforms that reduce operational overhead.

Strategic Initiatives:

• VA Deployment: Letter of Intent (LOI) received for enterprise deployment; negotiations for a definitive agreement are underway with implementation expected to begin early 2027. No revenue recognized from VA previously; new revenue expected to be additive starting potentially in 2027.
• DHA Contract: Negotiating a direct, longer-term contract to convert the current agreement; expected to conclude in the near term (potentially current quarter or early next).
• Operational Restructuring: Continued efficiency drives and workflow changes (including AI integration) to maintain a lean cost structure despite new contract wins; no significant headcount growth expected even with large contract additions.
• Product Launches: Shipped a new member experience (reduced screens from 12 to 3) in Q3; SilverCloud US rollout is a current priority.
• Timeline: FY2027 guidance to be released February 16; VA and DHA contract start dates may push revenue realization into 2027.

Risks and Headwinds to Outlook:

• VA Contract Timing: Final contract terms, negotiation duration, and specific implementation start dates are undetermined and could delay revenue recognition.
• DHA Contract Conversion: Outcome of negotiations to convert the existing agreement to a direct contract remains pending.
• Churn: Potential for continued natural churn in de-emphasized business segments, though major structural churn is expected to abate.
• Market Adoption: Success relies on proving outcomes to shift pricing models; delays in customer adoption of new engagement tools could impact utilization metrics.
• Macro Factors: Stubbornly high healthcare costs and premium pressure may influence buyer behavior if technology solutions do not demonstrate immediate ROI.

Management Tone on the Future:

• Confidence Level: High confidence in achieving Q4 break-even/positive EBITDA and positive cash flow from operations for FY2026.
• Trend Consistency: Highlighted "nine quarters in a row" of delivering commitments; described the current position as "more strategically and operationally focused than ever before."
• Strategic Clarity: Emphasis on "discipline" and "focus" on a single platform; rejecting the sale of isolated AI features in favor of a trusted platform hosting AI-powered care with human oversight.
• Hedges: Avoidance of specific 2027 numerical guidance due to dependence on contract finalization dates; cautious optimism regarding VA/DHA timelines.